Who is sponsoring NCT03764696?

NCT03764696 is sponsored by Navy General Hospital, Beijing.

What drugs are being tested in NCT03764696?

Interventions in NCT03764696: tight-fitting simple facemask.

What condition does NCT03764696 study?

NCT03764696 studies Oxygen Inhalation Therapy, Labour, Fetal Distress.

Is NCT03764696 still recruiting?

NCT03764696 is currently completed. Last updated 15 August 2023.

Last reviewed 2023-08-15 · How we verify

NCT03764696

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maternal Oxygen Administration for Fetal Distress II

Completed NA Last updated 15 August 2023

What this trial tests

NA trial testing tight-fitting simple facemask in Oxygen Inhalation Therapy in 140 participants. Completed in 31 December 2021.

Timeline

1 January 2021

Primary endpoint
31 October 2021

31 December 2021

Quick facts

Lead sponsor	Navy General Hospital, Beijing
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	140
Start date	1 January 2021
Primary completion	31 October 2021
Estimated completion	31 December 2021
Sites	3 locations across China

Drugs / interventions tested

tight-fitting simple facemask

Conditions studied

Oxygen Inhalation Therapy — all drugs for Oxygen Inhalation Therapy →
Labour — all drugs for Labour →
Fetal Distress — all drugs for Fetal Distress →

Sponsor

Navy General Hospital, Beijing

Who can join

Adults 18 to 40, female only, with Oxygen Inhalation Therapy or Labour. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Supplementary oxygen is routinely administered to patients, even those with adequate oxygen saturations, in the belief that it increases oxygen delivery. However, oxygen delivery depends not just on arterial oxygen content but also on perfusion. Maternal oxygen administration has been used in an attempt to lessen fetal distress by increasing the available oxygen from the mother. However, the effect of supplemental maternal oxygen therapy on fetal acid base status has been debated for more than seven decades. The investigators found the use of 2 L/min maternal oxygen during the second stage of labor did not adversely affect either the umbilical artery pH value or the fetal heart rate (FHR) pattern distribution.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effect of intrapartum prolonged oxygen exposure on fetal metabolic status: secondary analysis from a randomized controlled trial.
Chuai F, Dong T, Liu Y, Jiang W, et al · · 2023 · PMID 37441500 · DOI 10.3389/fendo.2023.1204956

Verify or expand the search:

Other recruiting trials for Oxygen Inhalation Therapy

Currently open trials in the same condition.

NCT05891886 — Supplemental Oxygen in Pulmonary Embolism (SO-PE) · EARLY_PHASE1 · recruiting

Other Navy General Hospital, Beijing trials

Trials by the same sponsor.

NCT06382038 — Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism · NA · not yet recruiting
NCT07184788 — G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma · Phase 2 · not yet recruiting
NCT06938893 — Study on Cardiac Output Evaluation Based on Wearable Monitoring Data · not yet recruiting
NCT06744894 — SIL as Maintenance Therapy in Multiple Myeloma · Phase 2 · not yet recruiting
NCT06350344 — Smart Technology Facilitated Patient-centered Venous Thromboembolism Management · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03764696 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Navy General Hospital, Beijing
Last refreshed: 15 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03764696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing